For example, CD28, CD40, and TNFRSF4 (OX40) antagonists are in early stage clinical trials for treatment of various immune disorders, whereas CD28, CD40, and TNFRSF4 (OX40) agonists are in early stage clinical trials for various cancer indications (Table 10). The gene discussed is CD28; the disease is cancer.